Ribometrix is a drug-discovery company leading a new paradigm in small molecule therapeutics that modulate RNA biology.
Our industry-leading drug discovery platform enables us to leverage proprietary RNA structure determination, state-of-the-art RNA tools and technologies, and complementary AI/ML capabilities to directly target and modulate RNA biology.
We employ two independent but related strategies to develop small molecule therapeutics:
- direct targeting of complex RNA structures, and
- disrupting RNA/RNA-binding protein interactions.
We believe our commitment to this new paradigm will deliver innovative new therapies to patients.